Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Haga clic en Calderaro Lancet Oncol 2023 to share.pdf para ver el archivo.